Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The prospective study of blood biomarker and gut microbiota in the patients treated with anti-PD 1 antibody for advanced non-small cell lung cancer

Next Previous
Trial Profile

The prospective study of blood biomarker and gut microbiota in the patients treated with anti-PD 1 antibody for advanced non-small cell lung cancer

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Mar 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 08 Mar 2020 Planned End Date changed from 30 Sep 2019 to 30 Sep 2023.
  • 22 Mar 2019 Planned End Date changed from 30 Apr 2019 to 30 Sep 2019.
  • 26 Apr 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top